OncoTargets and Therapy (Apr 2020)

MiR-138 Suppresses the PDK1 Expression to Decrease the Oxaliplatin Resistance of Colorectal Cancer

  • Wang Y,
  • Zhang D,
  • Li Y,
  • Fang F

Journal volume & issue
Vol. Volume 13
pp. 3607 – 3618

Abstract

Read online

Yao Wang, Duo Zhang, Yao Li, Fang Fang Inspection Institute, Jilin Medical University, Jilin City, Jilin Province 132013, People’s Republic of ChinaCorrespondence: Fang Fang No. 5, Jilin Street, Jilin City, Jilin Province 132013, People’s Republic of ChinaEmail [email protected]: Oxaliplatin is one kind of platinum-based drug. It is effective and commonly used in the treatment of colorectal cancer (CRC). However, development of acquired drug resistance is still a big obstacle during the oxaliplatin therapy. It is urgent to take strategies to decrease the oxaliplatin resistance of CRC.Materials and Methods: Oxaliplatin-resistant HT29 and SW480 (HT29/R and SW480/R) cells were acquired through long-term exposure to oxaliplatin by using the routine HT29 and SW480 cells. Relative glucose consumption, lactate generation and LDH activity were tested to evaluate the glycolysis of CRC cell lines. MTT assays were conducted to evaluate the differences of oxaliplatin sensitivity between HT29/R (SW480/R) cells and their parental HT29 (SW480) cells. Regulation of miR-138 on PDK1 was confirmed through qRT-PCR, Western blot and dual-luciferase reporter assays. Reactive oxygen species (ROS) levels were measured by flow cytometry.Results: HT29/R and SW480/R cells exhibited higher glucose consumption, lactate production and LDH activity compared to their parental HT29 and SW480 cells. However, oxygen consumption rate (OCR) in HT29/R and SW480/R cells is lower than that in HT29 and SW480 cells, respectively. Results of MTT assays showed that treatment with miR-138 can increase the cytotoxicity of oxaliplatin to HT29/R and SW480/R cells. Research on mechanisms showed that PDK1 was the target of miR-138. Overexpression of miR-138 can inhibit the expression of PDK1, and thus increase the OCR of HT29/R and SW480/R cells. Under the treatment of oxaliplatin, the miR-138-overexpressed HT29/R and SW480/R cells generated more amount of ROS to get into the apoptosis process.Conclusion: Overexpression of miR-138 suppressed the PDK1 expression to decrease the oxaliplatin resistance of CRC.Keywords: miR-138, oxaliplatin, colorectal cancer, PDK1

Keywords